Table 1.
Characteristics of the study group.
| Characteristics | Total |
|---|---|
| Number of patients | 51 (100) |
| Gender | M: 24 (47.06) |
| F: 27 (52.94) | |
| Age | 59.53 ± 8.85 |
| mean + SD (range) | (35.46–71.89) |
| Treatment | |
| VCD | 29 (56.86) |
| VTD | 5 (9.80) |
| CTD | 12 (23.53) |
| Other | 5 (9.80) |
| Bortezomib-based induction regimen | |
| Yes | 35 (68.63) |
| No | 16 (31.37) |
| Paraprotein | |
| IgG | 37 (72.55) |
| IgA | 4 (7.84) |
| IgM | 1 (1.96) |
| LCD Lambda | 5 (9.80) |
| LCD Kappa | 4 (7.84) |
| Bone disease at diagnosis | 34 (66.67) |
| Calcium > 2.75 mmol/L at diagnosis | 4 (7.84) |
| HB < 10 g/dL at diagnosis | 10 (19.61) |
| Creatinine > 2 mg/dL at diagnosis | 6 (11.76) |
| International Staging System (ISS) | I-18 (35.29) |
| II-14 (27.45) | |
| III-19 (37.25) | |
| Conditioning regimen | |
| Mel-175, 140, 100 | 17 (33.3) |
| Mel-200 | 34 (66.67) |
| Cytogenetics* | N = 13 |
| t(4;14) | 1 |
| t(14;16) | 2 |
| del(17p) | 1 |
| t(11;14) | 2 |
| Cytogenetic risk groups | |
| High Risk | 4 (7.84) |
| Standard Risk | 9 (17.65) |
| Unknown Risk | 38 (74.51) |
| Response before AHSCT | |
| CR | 8 (15.69) |
| VGPR | 22 (43.14) |
| PR | 16 (31.37) |
| SD | 3 (5.88) |
| missing | 2 (3.92) |
| Response after AHSCT | |
| CR | 17 (33.33) |
| VGPR | 18 (35.29) |
| PR | 9 (17.65) |
| SD | 2 (3.92) |
| PD | 1 (1.96) |
| missing | 4 (7.84) |
*Cytogenetics data were available for 13 patients (25.49%).